RNAZ — TransCode Therapeutics, Inc.

RNAZ (TransCode Therapeutics) Q4 2021 Earnings Call Summary

1. Key Financial Results and Metrics

• R&D Expenses: Increased significantly to $2.8 million in 2021 from $284,000 in 2020, primarily due to manufacturing and payroll expenses.
• General and Administrative Expenses: Rose to $3.4 million in 2021 compared to $440,000 in 2020, reflecting costs associated with being a public company.
• Net Loss: Reported at $6.8 million or $0.81 per share, up from a loss of $2.3 million or $0.51 per share in 2020.
• Cash Position: As of December 31, 2021, cash reserves were $20.8 million, expected to sustain operations into Q1 2023.

2. Strategic Updates and Business Highlights

• TransCode is advancing its lead therapeutic candidate, TTX-MC138, targeting microRNA-10b to treat metastatic cancer, with plans to file an eIND for a first-in-human clinical trial in 2022.
• The company has expanded its therapeutic pipeline from one to six candidates and two diagnostic assays, utilizing various RNA approaches including RNA interference (RNAi), CRISPR, and mRNA vaccines.
• A proprietary delivery system has been developed to enhance the efficacy of RNA therapeutics, claiming to achieve up to 98% delivery into cancer cells, a significant improvement over existing systems.

3. Forward Guidance and Outlook

• The company anticipates initiating a Phase 0 clinical trial later in 2022, pending FDA approval, to validate the delivery of RNA therapeutics and establish minimum effective dosing.
• Management expressed confidence in the potential of their therapeutic candidates to address significant unmet needs in cancer treatment, particularly for metastatic disease.

4. Bad News, Challenges, or Points of Concern

• The increase in R&D and administrative expenses raises concerns about cash burn as the company advances its clinical programs.
• The reliance on FDA approval for the eIND application introduces regulatory risks that could delay clinical trials.
• Competitive pressures exist in the oncology space, particularly from established therapies and other companies targeting similar RNA mechanisms.

5. Notable Q&A Insights

• Management confirmed that the Phase 0 trial will involve approximately 10 patients, with a focus on evaluating the delivery success of the therapeutic.
• Initial results from the trial may be reported shortly after completion, although detailed findings will take longer to finalize.
• There was an emphasis on the innovative nature of the Phase 0 trial, which aims to address the critical challenge of delivering RNA therapeutics effectively to tumor cells.

Overall, TransCode Therapeutics is positioned for significant developments in its therapeutic pipeline, although it faces financial and regulatory challenges that could impact its progress.